그룹 토론

This session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. It will be followed by a refreshment break in the exhibit hall.

11월 28일(수) | 14:50-16:00

Preclinical Models for Cancer Immunotherapy and Combinations

Preclinical Modeling and Combination Therapy Development: Models and Strategies

Moderators: 

Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich 

Michael Rugaard Jensen, PhD, Director, Head of ONC Discovery Pharmacology Basel, Novartis Institutes for BioMedical Research

  • Advantages and limitations of preclinical mouse models for immunotherapy evaluation
  • How can 3D models help drug discovery in cancer immunotherapy?
  • What other animal species, besides the mouse, could be evaluated for in vivo testing of cancer immunotherapies?
  • Combination therapy: preclinical considerations

Next Generation 3D Models and Co-Clinical Trials
Moderator:
Christian Schmees, PhD, Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen

Optimizing Leads and Predicting Drug Toxicity

Drug Bioactivation: The Good, The Bad and The Ugly
Moderator:
Axel Pähler, E.R.T., DMPK/PD Leader, Pharmaceutical Sciences (PS), Roche Pharmaceutical Research and Early Development, Roche Innovation Center

  • Bioactivation as a risk factor for drug induced toxicities such as DILI
  • Case studies of reactive metabolite formation linked to safety failures and key learnings
  • Bioactivation reactions that determine the pharmacological mode of action
  • Key learnings from old drugs and novel strategies to design selective new inhibitors for safe use

Improving In vitro to In vivo Predictions
Moderator:
Christopher Goldring, PhD, Senior Lecturer, Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool

  • Safety testing roadmap being developed by IMI MIP-DILI and TransQST consortia
  • Integration of established and emerging test systems - 2D to multi-cell 3D systems
  • Use of stem cells in safety assessments

Target Identification & Validation Strategies

CRISPR/Cas9 for Drug Discovery Applications
Moderators:
John Doench, PhD, Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT
Michael Bassik, PhD, Assistant Professor, Department of Genetics, Stanford University

  • Impact of CRISPR/Cas9 for drug discovery in pharma and academia
  • Applications for functional screens, creating cell lines and disease models
  • Design and optimization of low- and high-throughput screens using CRISPR approaches
  • Application of CRISPR-knockout, -activation and -inhibition
  • Impact of new CRISPR technologies and reagents

Use of Chemical Biology and Chemical Probes in Drug Discovery
Moderator:
Paul Brennan, Ph.D., Associate Professor, Medicinal Chemistry, University of Oxford and Principal Investigator, Target Discovery Institute, Structural Genomics Consortium

  • Main applications of Chemical Biology in Drug Discovery projects
  • When should Chemical Biology be used in Discovery programs?
  • Labelled and label-free proteomic techniques for target identification

NASH and Fibrosis: Translational Research and Strategies

Animal Models for Fibrosis
Moderator:
Bryan C. Fuchs, PhD, Assistant Professor of Surgery, Harvard Medical School

  • Who has used what?
  • Pros and cons of different models
  • What looks promising

NASH Drug Development Challenges
Moderator:
Dean W. Hum, PhD, CSO, Genfit

  • Role of biomarkers
  • European v. FDA guidance
  • Defining target population

11월 29일(목) | 15:05-16:05

3D Cellular Models

Microphysiological Systems for Drug Screening
Moderator:
Hansjoerg Keller, PhD, Sr. Investigator I, Musculoskeletal, Novartis Institutes for BioMedical Research

  • Key advantages over classical 2D cell culture models
  • Reliability and translatability of human systems
  • Applicability, throughput and cost effectiveness

Induced Pluripotent Stem Cells

Human Pluripotent Stem Cells and Their Use as A Massive Platform for Organoid Generation
Moderator:
Nuria Montserrat, PhD, Group Leader, Pluripotency for organ regeneration, Institute for Bioengineering of Catalonia (IBEC)

  • How to benefit from bioengineering approaches in order to enhance organoid maturation/vascularization
  • Immediate applications from 3D bioprinting using organoids
  • Ethic issues related to the use of human pluripotent stem cells

Translational Biomarkers in Immuno-Oncology

Immunological Determinants of Response to Systemic Therapy In Cancer
Moderator:
Sofia Braga, MD, PhD, Assistant Professor, Instituto CUF Oncologia, NOVA Medical School

  • Neoplastic cell attributes: 
    1. Neo antigen load
    2. Mutational burden
    3. Mismatch repair deficient cells / high microsatelite instability 
  • Immune system atributes:
    1. Baseline T cell infiltration: cytotoxic "antitumor" T cells, low tolerogenic T cells
    2. Other ancillary molecules: PDL1, CD8, B2M 
    3. TCR sequencing
    4. T cell clones
    5. Intact immunity 

Liquid Biopsy in IO research
Moderator:
Evi Lianidou, PhD, Professor of Clinical Chemistry, University of Athens

  • Tumor diagnosis, monitoring, and treatment
  • Blood tests / biomarkers
  • Mutational analysis of tumors and blood

CNS Models and Translational Strategies

Dish, Animal or Patient: How Can We Best Understand Neurodegenerative Disease?
Moderator:
Stuart W. Hughes, PhD, Director and Head of Pharmacology, Biological Sciences, Vertex Pharmaceuticals

  • Is failure in neurodegenerative diseases related to a focus on inappropriate models?
  • Can neurodegeneration truly be modeled in vitro?
  • Should we pursue the biology of causation or progression?
  • What does a ‘validate target’ mean when it comes to neurodegenerative diseases?

Should a Robust Translational Path from Animals to Humans be Required to Advance a Compound?
Moderator:
William Z. Potter MD, PhD, Senior Advisor, National Institute of Mental Health, National Institutes of Health (NIH)

  • Should a biomarker of drug effect in human brain always be required  to advance a novel compound into efficacy studies
  • Does there need to be preclinical data with a homologous biomarkers (e.g. fMRI for both animals and humans)?
  • If not, what constitutes adequate evidence that some brain effect observed in animals is occurring in humans?
  • Given clinical need are there arguments to advance compounds with some biomarker of acute effect?

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English



Catalog Download
Catalog




메일링 서비스